第58届美国临床肿瘤学会（ASCO）年会即将于美国当地时间2022年6月3日～7日举行，「肿瘤资讯」整理了会上将进行报告的肺癌相关口头报告研究，供您参考。
口头报告专场（Oral Abstract Section）
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for patients with stage III-N2M0 non-small cell lung cancer (NSCLC): A population-based study.
第一作者：Marah Akhdar
Amivantamab和lazertinib用于奥希替尼和铂类化疗后进展的EGFR突变非小细胞肺癌（NSCLC）的试验更新结果(CHRYSALIS-2研究)
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
第一作者：Catherine A. Shu MD
KRAS抑制剂MRTX849用于治疗KRAS G12C突变的晚期/转移性非小细胞肺癌（NSCLC）的疗效与安全性分析（KRYSTAL-1研究）
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation.
第一作者：Alexander I. Spira FACP, MD, PhD
两周期与三周期的新辅助信迪利单抗联合铂类双药化疗在可切除非小细胞肺癌患者中的疗效对比(neoSCORE)：随机对照、单中心、II期试验
Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
第一作者：邱福铭教授 浙江大学医学院附属第二医院
雷莫西尤单抗+帕博利珠单抗用于早期接受过免疫治疗的晚期非小细胞肺癌患者总生存率研究：II期、随机的研究(Lung-MAP nonmatched substudy S1800A)
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
第一作者：Karen L. Reckamp MD
广泛性小细胞肺癌的加强免疫治疗
Enhancing Immunotherapy for Extensive Small Cell Lung Cancer
第一作者：Chandra Prakash Belani MD
PD-L1未选择人群中使用可溶性LAG-3蛋白eftilagimod alpha联合帕博利珠单抗一线治疗转移性非小细胞肺癌的II期试验（TACTI-002）的最新结果
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population
第一作者：Enriqueta Felip PhD, MD
PD-1/PD-L1单抗联合或不联合化疗用于一线治疗PD-L1表达≥50%晚期非小细胞肺癌的FDA汇总分析
Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
第一作者：Oladimeji Akinboro MD, MPH
Amivantamab用于治疗MET14外显子跳跃突变非小细胞肺癌的CHRYSALIS试验更新结果
Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study
第一作者：Matthew Krebs FRCP, PhD
随机接受大剂量胸腔放疗(TRT)和标准每日两次(BID)胸腔放疗的局限期小细胞肺癌患者(LS-SCLC)的生活质量对比(CALGB 30610研究)
Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).
第一作者：Apar Kishor Ganti MD
肺癌术中质量指标与术后生存率间的关联
Intraoperative quality metrics and association with survival following lung cancer resection.
第一作者：Brendan Heiden MD
PD-1单抗斯鲁利单抗联合化疗 vs 单独化疗一线治疗广泛期小细胞肺癌的一项国际、随机III期研究
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
第一作者：程颖教授 吉林省肿瘤医院
SKYSCRAPER-02：阿替利珠单抗+化疗±TIGIT抑制剂tiragolumab用于一线治疗未经治疗的广泛期小细胞肺癌(ES-SCLC)的III期随机双盲初步研究结果
SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
第一作者：Charles M. Rudin PhD, MD
卡博替尼+阿替利珠单抗vs卡博替尼单药治疗既往接受过免疫检查点抑制剂（ICI）治疗的晚期非小细胞肺癌患者（aNSCLC）：COSMIC-021研究7&20队列的结果分析
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
第一作者：Joel W. Neal PhD, MD
EGFR抑制剂CLN-081用于治疗EGFR20号外显子插入突变(Ins20)非小细胞肺癌的I/IIa期试验
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
第一作者：Helena Alexandra Yu MD
纳武利尤单抗+化疗 vs 化疗新辅助治疗可切除IIIA期非小细胞肺癌患者：II 期 NADIM试验病理完全缓解 (pCR)主要终点结果。
Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
第一作者：Mariano Provencio-Pulla MD, PhD
根据KRAS突变状态和PD-L1表达，一线免疫检查点抑制剂±化疗治疗晚期非小细胞肺癌的疗效：FDA汇总分析
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
第一作者：Erica C. Nakajima MD
海报讨论专场（Poster Discussion Section）
针对IL1RAP的first-in-class全人源化单克隆抗体nadunolimab+顺铂+吉西他滨（CG）联合治疗非小细胞肺癌（NSCLC）患者的1/2a期试验
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
第一作者：Astrid Paulus
晚期非鳞状非小细胞肺癌患者的综合分子基因分型与总生存期的关系
题目：Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.
第一作者：Charu Aggarwal MD, MPH
晚期非小细胞肺癌（NSCLC）患者对PD-(L)1阻断剂产生获得性耐药的基因组相关因素
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
第一作者：Biagio Ricciuti MD
铂类和抗PD(L)1治疗失败后，Sunvozertinib在EGFR20号外显子插入突变的非小细胞肺癌患者中的抗肿瘤活性
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
第一作者：Pasi A. Janne MD, PhD
AK112（PD-1/VEGF双特异性）联合化疗治疗晚期非小细胞肺癌患者的II期临床研究
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
第一作者：Yuangyuan Zhao
ETCTN加州癌症联盟：奥希替尼+ necitumumab单抗用于治疗EGFR突变型非小细胞肺癌I期研究的最终结果
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
第一作者：Jonathan W. Riess MD, MS
瞄准肺外小细胞神经内分泌癌的基因组不稳定性ATR抑制剂berzosertib和topotecan的II期研究
Targeting genomic instability in extrapulmonary small cell neuroendocrine cancers: A phase II study with ATR inhibitor berzosertib and topotecan.
第一作者：Nobuyuki Takahashi MD, PhD
KEYNOTE-799：帕博利珠单抗+同期化放疗（cCRT）用于治疗不可切除、局部晚期、III期非小细胞肺癌的两年更新研究
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
第一作者：Martin Reck MD, PhD
持续talazoparib（TALA）+间歇性低剂量的替莫唑胺（TMZ）治疗复发或难治的广泛期小细胞肺癌（ES-SCLC）患者的2期研究初步分析
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
第一作者：Jonathan W. Goldman MD
纳武利尤单抗+伊匹木单抗或单独纳武利尤单抗用于不可切除的III期非小细胞肺癌患者化疗后巩固的研究（BTCRC LUN 16-081）
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
第一作者：Greg Andrew Durm MD
信迪利单抗+ anlotinib作为小细胞肺癌后线治疗的客观表现试验
Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.
第一作者：Shuxiang Ma
CheckMate 816：纳武利尤单抗新辅助+铂类双药化疗（化疗）vs化疗在治疗可切除（IB-IIIA）非小细胞肺癌（NSCLC）上病理回归与无事件生存（EFS）的关系
Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.
第一作者：Mariano Provencio-Pulla MD, PhD
EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091研究：帕博利珠单抗vs安慰剂治疗完全切除的早期非小细胞肺癌（NSCLC）在手术、疾病负担和辅助化疗使用相关亚组的结果
EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
第一作者：Mary E.R. O'Brien MD
Telisotuzumab vedotin (Teliso-V)单药治疗先前接受过c-Metovereigning (OE)治疗的晚期非小细胞肺癌（NSCLC）患者
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
第一作者：D. Ross Camidge MD, PhD
Patritumab deruxtecan (HER3-DXd)用于无EGFR激活突变的晚期/转移性非小细胞肺癌（NSCLC）的疗效和安全性分析
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
第一作者：Conor Ernst Steuer MD
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
第一作者：Jonathan W. Goldman MD
不同基因组和免疫表型特征的实体为主与非实体为主的I期肺腺癌在切除术后复发的差异
Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection.
第一作者：Joao Victor Machado Alessi MD
拉罗替尼用于原肌球蛋白受体激酶（TRK）融合型肺癌患者的疗效和安全性更新
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
第一作者：Alexander E. Drilon MD
针对局部晚期非小细胞肺癌的选择性个体化放射免疫治疗试验（SPRINT）的初步结果
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
第一作者：Nitin Ohri, MD, M
RAF/MEK钳制剂VS-6766联合依维莫司联、采用间歇性时间表，用于多种KRAS突变的非小细胞肺癌的I期试验
Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.
第一作者：Anna Rachel Minchom, MD, MB, BCh, MRCP
使用表面组分析方法分析小细胞肺癌不同转录亚型的治疗弱点
Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).
第一作者：Taofeek K. Owonikoko, MD, PhD,
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).
第一作者：Solange Peters, MD, PhD
NRG-LU004研究：加速或常规分割放疗联合PD-1单抗度伐利尤单抗治疗局部晚期非小细胞肺癌的I期试验的安全性结果
Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.
第一作者：Steven H. Lin, MD, PhD,
排版编辑：肿瘤资讯-Shire
苏公网安备32059002004080号
